Obesity Gene-Edited Cell Models for Drug Discovery

Obesity is a global epidemic, with the World Health Organization (WHO) reporting that over 650 million adults were obese in 2016, a number that has tripled since 1975. Obesity is a major risk factor for type 2 diabetes, cardiovascular disease, hypertension, and certain cancers. According to the National Cancer Institute (NCI), obesity is associated with increased risk and poorer prognosis for at least 13 cancer types, including breast, colorectal, and pancreatic cancers. The economic burden is substantial, with healthcare costs in the billions annually.

Obesity is a complex, multifactorial disease involving genetic, environmental, and behavioral factors. It is ideal for mechanistic studies due to its well-characterized metabolic pathways and the availability of public datasets such as the Genome-Wide Association Studies (GWAS) catalog and the UK Biobank. Key open questions include the molecular basis of leptin resistance, the role of brown adipose tissue in energy expenditure, and the identification of novel drug targets for weight loss.

Obesity pathogenesis involves dysregulation of energy homeostasis, primarily through the following pathways:

1. Leptin-Melanocortin Pathway: Leptin from adipose tissue activates the melanocortin system in the hypothalamus, suppressing appetite. Mutations in leptin (LEP), leptin receptor (LEPR), or melanocortin 4 receptor (MC4R) cause hyperphagia and early-onset obesity.

2. Insulin Signaling Pathway: Insulin regulates glucose uptake and lipid storage. Insulin resistance in adipose tissue and muscle leads to metabolic dysfunction.

3. Adipogenesis Pathway: PPARG and C/EBP transcription factors drive differentiation of preadipocytes into mature adipocytes. Dysregulation contributes to adipose tissue expansion.

4. Energy Expenditure Pathway: Uncoupling protein 1 (UCP1) in brown adipose tissue dissipates energy as heat. Reduced UCP1 activity is linked to obesity.

Data sourced from NCBI Gene, ClinVar, and GWAS catalog.

Key signaling networks in obesity include:

• • Leptin-JAK/STAT pathway: Leptin binding to LEPR activates JAK2 and STAT3, leading to POMC expression. Mutations disrupt this cascade.
• • Insulin-PI3K/AKT pathway: Insulin receptor activation leads to PI3K/AKT signaling, promoting glucose uptake and lipid synthesis. Resistance impairs these processes.
• • AMPK pathway: AMPK acts as an energy sensor, inhibiting anabolic pathways and promoting catabolism. Dysregulation contributes to metabolic imbalance.
• • Adipokine signaling: Adipose tissue secretes adipokines (e.g., adiponectin, resistin) that modulate insulin sensitivity and inflammation. Altered secretion is a hallmark of obesity.

Organoids derived from adipose tissue or intestinal cells offer 3D models that recapitulate tissue architecture and cell-cell interactions, providing more physiologically relevant systems for studying obesity.

Animal models for obesity research include:

• • Diet-induced obesity (DIO) models: Mice fed a high-fat diet develop obesity and insulin resistance.
• • Genetic models: ob/ob mice (leptin deficiency) and db/db mice (leptin receptor deficiency) exhibit severe obesity.
• • Genetically engineered mouse models (GEMMs): Knockout or transgenic mice for genes like MC4R, POMC, or PPARG.
• • Patient-derived xenografts (PDX): Not common for obesity; used for obesity-associated cancers.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as knockout or knock-in of obesity-related genes. For example, LEPR knockout in 3T3-L1 cells models leptin resistance, while MC4R knockout in hypothalamic neurons recapitulates hyperphagia. PPARG knockout in preadipocytes blocks adipogenesis. Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent, validated tools for functional studies, drug screening, and target validation.

Gene-edited cell lines are used to validate the role of candidate genes in obesity. For instance, knockout of FTO in 3T3-L1 cells reduces adipogenesis, confirming its role in fat cell development. Knock-in of MC4R mutations in neuronal cell lines allows study of receptor signaling and identification of compensatory mechanisms.

Isogenic pairs (e.g., wild-type vs. LEPR knockout) are used in high-throughput screens to identify compounds that bypass leptin resistance. For example, screening for agonists that activate downstream signaling in LEPR-deficient cells can uncover novel anti-obesity drugs. Resistance modeling involves exposing cells to drugs like orlistat and studying genetic adaptations.

CRISPR screens can identify genes whose knockout sensitizes cells to anti-obesity treatments, revealing synthetic lethal interactions. For example, a genome-wide CRISPR screen in adipocytes treated with a PPARG agonist can identify genes that enhance or suppress adipogenesis, providing biomarkers for patient stratification.